,42 Among the first-generation mAbs, the earliest CTLA-4 inhibitor ipilimumab and PD-1 inhibitor nivolumab/pembrolizumab have become first-line therapeutic options in advanced non-small cell lung cancer and melanoma cases.43 Here, CTLA4 is linked to non-small cell lung carcinoma.